相似文献
1
Evolving Approaches for Pharmacological Therapy of Obesity.
Annu Rev Pharmacol Toxicol. 2025 Jan;65(1):169-189. doi: 10.1146/annurev-pharmtox-031124-101146. Epub 2024 Dec 17.
2
Incretin-based therapies for obesity treatment.
Metabolism. 2015 Sep;64(9):967-81. doi: 10.1016/j.metabol.2015.05.012. Epub 2015 May 23.
3
Incretin hormone agonists: Current and emerging pharmacotherapy for obesity management.
Pharmacotherapy. 2024 Sep;44(9):738-752. doi: 10.1002/phar.4607. Epub 2024 Sep 3.
4
Glucagon-like peptide-1 receptor agonists: the key to healthy weight loss maintenance?
Cardiovasc Res. 2021 Aug 29;117(10):e120-e122. doi: 10.1093/cvr/cvab249.
5
Emerging pharmacotherapies for obesity: A systematic review.
Pharmacol Rev. 2025 Jan;77(1):100002. doi: 10.1124/pharmrev.123.001045. Epub 2024 Nov 22.
6
The incretin pathway as a new therapeutic target for obesity.
Maturitas. 2010 Nov;67(3):197-202. doi: 10.1016/j.maturitas.2010.06.018. Epub 2010 Jul 23.
7
Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial.
Int J Obes (Lond). 2021 Aug;45(8):1687-1695. doi: 10.1038/s41366-021-00831-4. Epub 2021 Jun 3.
8
Incretin-Based Therapies and Lifestyle Interventions: The Evolving Role of Registered Dietitian Nutritionists in Obesity Care.
J Acad Nutr Diet. 2025 Mar;125(3):408-421. doi: 10.1016/j.jand.2024.10.023. Epub 2024 Nov 7.
9
Review article: Pharmacologic management of obesity - updates on approved medications, indications and risks.
Aliment Pharmacol Ther. 2024 Feb;59(4):475-491. doi: 10.1111/apt.17856. Epub 2024 Jan 2.
10
Treating the obese diabetic.
Expert Rev Clin Pharmacol. 2013 Mar;6(2):171-83. doi: 10.1586/ecp.13.5.
引用本文的文献
1
Probiotic Potentials and Protective Effects of LA-1 Against High-Fat Diet-Induced Obesity in Mice.
Nutrients. 2025 Jul 17;17(14):2346. doi: 10.3390/nu17142346.
2
Psychological Traits of Bariatric Surgery Candidates and Predictors of Outcomes.
J Pers Med. 2025 May 26;15(6):215. doi: 10.3390/jpm15060215.
本文引用的文献
1
Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults.
Lancet. 2024 Mar 16;403(10431):1027-1050. doi: 10.1016/S0140-6736(23)02750-2. Epub 2024 Feb 29.
2
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.
Lancet Diabetes Endocrinol. 2024 Mar;12(3):162-173. doi: 10.1016/S2213-8587(23)00356-X. Epub 2024 Feb 5.
3
A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings.
Nat Metab. 2024 Feb;6(2):290-303. doi: 10.1038/s42255-023-00966-w. Epub 2024 Feb 5.
4
A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity.
Nat Commun. 2023 Dec 14;14(1):8289. doi: 10.1038/s41467-023-44067-4.
5
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
JAMA. 2024 Jan 2;331(1):38-48. doi: 10.1001/jama.2023.24945.
6
The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities.
Curr Obes Rep. 2023 Dec;12(4):453-473. doi: 10.1007/s13679-023-00534-z. Epub 2023 Dec 2.
7
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11.
8
Effects of CB1R inverse agonist, INV-202, in patients with features of metabolic syndrome. A randomized, placebo-controlled, double-blind phase 1b study.
Diabetes Obes Metab. 2024 Feb;26(2):642-649. doi: 10.1111/dom.15353. Epub 2023 Nov 8.
9
Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial.
Nat Med. 2023 Nov;29(11):2909-2918. doi: 10.1038/s41591-023-02597-w. Epub 2023 Oct 15.
10
Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial.
Lancet Gastroenterol Hepatol. 2023 Dec;8(12):1094-1105. doi: 10.1016/S2468-1253(23)00198-X. Epub 2023 Oct 5.
Zotero 插件